International Psoriasis Council

Advancing Knowledge. Improving Care.

Liangdan

Sun

,

MD, PhD

Director
Health Science Center of North China University of Science and Technology
Hebei Province
,
China
Councilor Since: March 17, 2023
IPC Councilor
Dr. Liangdan Sun is a renowned professor and Vice President of the North China University of Science and Technology (NCUST) in Tangshan, Hebei Province, China. He is the Director of the Health Science Center, the Director of the Inflammation and Immune Diseases Laboratory of NCUST, and a Visiting Scholar at the University of Colorado and the Royal Swedish Academy of Engineering Sciences.

Dr. Sun’s primary research focuses on translational genomics, precision medicine, and mechanisms of genetic susceptibility to inflammation and immune diseases. He has identified over 200 susceptibility genes and diagnostic biomarkers for 40 diseases. Moreover, he has constructed a unique precision variation database of the whole Human Leukocyte Antigens (HLA) based on 10,000 samples from the Chinese population. He has created genome-wide variation maps for different diseases through genome-wide association and sequencing studies and demonstrated the mechanisms of genetic susceptibilities and etiologies. This research has provided necessary evidence for the precision medicine of these diseases.

Dr. Sun is a prolific author with over 210 published papers. His work has been featured in prestigious journals such as Nat Genet, New Engl J Med, and Nat Commun. He has been cited more than 12,000 times, including publications in top-tier journals such as Nature, Cell, Science, and New Engl J Med.
Last Updated:
04/29/2023

Areas of Interest

Translational genomics, precision medicine, and mechanisms of genetic susceptibility of inflammation and immune diseases

IPC Committees / Groups

Regional Development Task Force

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026